Vencore

[REPORT] How are Big Data Analytics Revolutionizing Rare Disease Patient Discovery & Commercialization Strategies?

In Clinical Development, Orphan Drug Congress, Orphan Drugs Live by Freya SmaleLeave a Comment

Report on how are Big Data Analytics Revolutionizing Rare Disease Patient Discovery & Commercialization Strategies provided by Vencore

In the world of “traditional” pharma we are used to thinking about finding our market via population segmentation and targeting. When we have a new drug for diabetes, or reflux, or hypertension, it isn’t hard to find patients. Rather, there are so many patients we have to prioritize. We have to figure out which of the millions of patients could be taking our new drug. We can easily obtain lists of patients on competitor drugs, or doctors who prescribe frequently, and then target those populations.

But in the world of rare disease and orphan drugs, life is more complicated. Many of the tools that we take for granted in the world of diabetes are unavailable to us in rare disease.  It’s not as simple as querying a database. When only 200 people in the country have the disease, and there is no marketed treatment, the question isn’t “which of the patients should we choose?” It is “how do we find as many patients as possible?” How do we connect these undiagnosed patients to therapy? How do we – quite literally – find our market?

Download the report on how Big Data Analytics Revolutionizing Rare Disease Patient Discovery & Commercialization Strategies >

Vencore are sponsoring the World Orphan Drug Congress USA 2016. Join them there by registering today >

World Orphan Drug Congress USA 2016

Leave a Comment